Organon To Present New Analysis Of Phase 3 Data Evaluating VTAMA Cream In Patients With Atopic Dermatitis, At 2026 ACAAI Annual Scientific Meeting
Benzinga Newsdesk 7 hours ago
News
New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroupsOrganon (NYSE:OGN), a global healthcare company with a mission to deliver
New pooled post-hoc analysis of Phase 3 data evaluates consistency of VTAMA cream efficacy across diverse atopic dermatitis patient subgroups
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in patients with moderate to severe atopic dermatitis (AD) will be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place in Phoenix, Arizona.
The analysis evaluates the efficacy of VTAMA cream across diverse patient subgroups based on baseline percent body surface area (BSA) affected and other baseline characteristics.